• Users Online: 128
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
BRIEF COMMUNICATION
Year : 2017  |  Volume : 6  |  Issue : 2  |  Page : 68-69

Dexrazoxane in anthracycline cardiotoxicity


Department of Anaesthesia and Pain Medicine, Basavatarakam Indo American Cancer Hospital and Research Centre, Hyderabad, Telangana, India

Correspondence Address:
Abhijit S Nair
Department of Anaesthesia and Pain Medicine, Basavatarakam Indo American Cancer Hospital and Research Centre, Hyderabad - 500 034, Telangana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2250-3528.203533

Rights and Permissions

Anthracycline group of antineoplastic agents is notorious for causing cumulative dose induced cardiotoxicity which is more pronounced in elderly patients and in patients with preexisting cardiac comorbidities. Several preventive strategies have been explored with variable success and without randomized studies and insufficient data. Dexrazoxane is an ethylenediaminetetraacetic acid analog which has been found to be effective when used before or along with anthracycline infusion. The drug is also found to be useful in counteracting injuries caused due to anthracycline extravasation in the tissues.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2263    
    Printed134    
    Emailed0    
    PDF Downloaded228    
    Comments [Add]    

Recommend this journal